DOCSLIB.ORG

39118-Sinapse 8 Mai2005.Qxd

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
39118-Sinapse 8 Mai2005.Qxd Sinapse® Publicação da Sociedade Portuguesa de Neurologia Versão electrónica em www.spneurologia.org Volume 5 | Nº1 | Maio de 2005 Indexada em www.indexrmp.com Orgão oficial de: Sociedade Portuguesa de Neurologia Liga Potuguesa Contra a Epilepsia Sociedade Portuguesa de Cefaleias Editorial Artigo de Homenagem O Dr. Castro Lopes, a Neurologia e as doenças cérebro-vasculares JM Pereira Monteiro Artigo de revisão Terapêutica Antigénio-Específica com Vacinação de ADN em Modelos Experimentais de Esclerose Múltipla: mecanismos e aplicações Paulo Fontoura, Hideki Garren, Peggy P. Ho, Pedro J. Ruiz, William H. Robinson, Lawrence Steinman Artigos originais Pesquisa Protocolada de Foramen Oval Patente com Doppler Transcraniano Codificado a Cor e sua Comparação com o Ecocardiograma Transesofágico Joana Guimarães, Rosa Santos, Graça Sousa, Pardal de Oliveira, Elsa Azevedo Adesão à Terapêutica Antiplaquetária na Prevenção Secundária do Acidente Isquémico Transitório João Paulo Gabriel, Ignácio Martin, Paula Ribeiro, Mário Rui Silva, Manuel Correia Meduloblastomas em Idade Tardia – série de cinco adultos com mais de 40 anos Paulo Bugalho, Francisco Mascarenhas, José Pimentel Distrofia Muscular das Cinturas Tipo 2I: apresentação dos primeiros casos clínicos portugueses Luís Negrão, Argemiro Geraldo, Olinda Rebelo, Anabela Marques, Rosário Santos, Luís Cunha Doenças Neuromusculares em Portugal na etnia cigana – um trabalho de colaboração com 63 Neuropediatras e Neurologistas Portugueses Manuela Santos Casos Clínicos Fibrinólise Local em Trombose Venosa Cerebral num Doente com Contraindicação para Anticoagulação Ana Paiva Nunes, Luísa Albuquerque, Luísa Biscoito, Jorge Campos, José Ferro A História do Senhor Sommer. Análise Linguística de um Discurso Afásico. José Fonseca, Luz Rocha Artigos especiais História da Pesquisa da Sensibilidade Francisco Pinto Morte Aparente nos Finais do Séc. XVIII António Leite Carneiro Relatório de Programas de Cirurgia da Epilepsia Dílio Alves, Fernando Gomes, José M. Lopes Lima, José Pimentel, Orlando Leitão Reuniões Nacionais Encontro Nacional de Epileptologia Normas para a organização de Encontros Nacionais de Epileptologia Resumos de comunicações Reunião da Sociedade Portuguesa de Neurociências Programa, resumos de comunicações Fórum de Neurologia 2005 Programa, resumos de comunicações Reunião do Grupo de Estudos de Esclerose Múltipla Sociedade Portuguesa de Resumos de comunicações Neurologia Sociedade Portuguesa de Neurologia Direcção Mesa da Assembleia Geral Conselho Fiscal Presidente Presidente Presidente António Freire Gonçalves Orlando Leitão Maria Helena Coelho Vice-Presidentes Secretários Vogais Maria Cristina Januário José M. Lopes Lima José Grilo Gonçalves Maria José Sá Lívia Diogo de Sousa José Vale dos Santos Teresa Pinho e Melo Tesoureiro Dílio Alves Sinapse® Publicação Semestral da Sociedade Portuguesa de Neurologia Órgão oficial de Sociedade Portuguesa de Neurologia; Liga Potuguesa Contra a Epilepsia; Sociedade Portuguesa de Cefaleias. Administração A. Freire Gonçalves, Maria José Sá, Dílio Alves. Ficha Editorial Director Conselho Científico José Barros A. Bastos Lima A. Castro Caldas Conselho Editorial Catarina Oliveira Alexandre de Mendonça Celso Pontes Belina Nunes José M. Ferro Fernando Pita J.M. Pereira Monteiro Luís Negrão Luís Cunha Mamede de Carvalho Paula Coutinho Paula Esperança Teresa Paiva Sinapse® Rua D. Manuel 11, 33, sala 41, 4050-345 Porto Tel / Fax: 351-22-6001553 Correio electrónico: Propriedade: Versão electrónica em [email protected] Sociedade Portuguesa de Neurologia www.spneurologia.org Registo de Marca: A Sinapse está disponível na base Secretariado editorial: 358 268 (Instituto Nacional de pesquisa bibliográfica Assunção Tuna e Nuno Vila Chã de Propriedade Industrial) www.indexrmp.com. Secretariado administrativo: ISSN: 1645-281X Ana Isabel Teixeira Depósito Legal: 172 674/01 Capa: Retrato de mulher passeando Design: Isabel Monteiro Tiragem: 600 exemplares pela mata da Serra do Buçaco. Produção gráfica: Edição: Publicação semestral; Aurélio Paz dos Reis. Multitema – Soluções de Impressão, S.A. Volume 5 – Número 1 – Maio de 2005 s/ data | cx289 APR3993 Produção da versão electrónica: Preço unitário: €10 ©Centro Português de Fotografia | WEBlink – Tecnologias de Informação, Lda. Assinatura anual: €15 Ministério da Cultura Sinapse – Volume 5 – Número 1 Os artigos publicados e outros trabalhos candidatos a este número foram avaliados e revistos por: A. Bastos Lima, A. Castro Caldas, Alexandre de Mendonça, Belina Nunes, Carla Ferreira, Catarina Oliveira, Celso Pontes, Fernando Pita, J.M. Pereira Monteiro, José M. Ferro, Luís Cunha, Luís Santos, Luís Negrão, Mamede de Carvalho, Paula Coutinho, Paula Esperança, Raimundo Martins. Cada um dos resumos de comunicações ao Fórum de Neurologia 2005 foi avaliado por dois revisores (selecionados pela Direcção da SPN a partir de um conjunto de cerca de trinta peritos independentes). Os resumos de comunicações ao 17º Encontro Nacional de Epileptologia foram avaliados e revistos pela respectiva Comissão Científica (Francisco Sales, Isabel Santana, José Pimentel, Lopes Lima). Os resumos de comunicações à Reunião da Sociedade Portuguesa de Neurociências são da responsabilidade editorial e científica desta organização. Os resumos de comunicações à Reunião de Primavera do Grupo de Estudos de Esclerose Múltipla foram avaliados e revistos pela Direcção do Grupo. As responsabilidades científica e ética dos trabalhos publicados são dos seus autores. Índice geral Pág. Ficha técnica. Princípios editoriais. Normas de publicação. Protocolo de cooperação. 7Editorial Artigo de homenagem 8O Dr. Castro Lopes, a Neurologia e as doenças cérebro-vasculares. JM Pereira Monteiro Artigo de revisão 11 Terapêutica Antigénio-Específica com Vacinação de ADN em Modelos Experimentais de Esclerose Múltipla: Índice geral Índice mecanismos e aplicações Paulo Fontoura, Hideki Garren, Peggy P. Ho, Pedro J. Ruiz, William H. Robinson, Lawrence Steinman Artigos originais 21 Pesquisa Protocolada de Foramen Oval Patente com Doppler Transcraniano Codificado a Cor e sua Comparação com o Ecocardiograma Transesofágico Joana Guimarães, Rosa Santos, Graça Sousa, Pardal de Oliveira, Elsa Azevedo 25 Adesão à Terapêutica Antiplaquetária na Prevenção Secundária do Acidente Isquémico Transitório João Paulo Gabriel, Ignácio Martin, Paula Ribeiro, Mário Rui Silva, Manuel Correia 29 Meduloblastomas em Idade Tardia – série de cinco adultos com mais de 40 anos Paulo Bugalho, Francisco Mascarenhas, José Pimentel 33 Distrofia Muscular das Cinturas Tipo 2I: apresentação dos primeiros casos clínicos portugueses Luís Negrão, Argemiro Geraldo, Olinda Rebelo, Anabela Marques, Rosário Santos, Luís Cunha 39 Doenças Neuromusculares em Portugal na etnia cigana – um trabalho de colaboração com 63 Neuropediatras e Neurologistas Portugueses Manuela Santos Casos clínicos 42 Fibrinólise Local em Trombose Venosa Cerebral num Doente com Contraindicação para Anticoagulação Ana Paiva Nunes, Luísa Albuquerque, Luísa Biscoito, Jorge Campos, José Ferro 46 A História do Senhor Sommer. Análise Linguística de um Discurso Afásico. José Fonseca, Luz Rocha Artigos especiais 53 História da Pesquisa da Sensibilidade Francisco Pinto 56 Morte Aparente nos Finais do Séc. XVIII António Leite Carneiro 60 Relatório de Programas de Cirurgia da Epilepsia Dílio Alves, Fernando Gomes, José M. Lopes Lima, José Pimentel, Orlando Leitão Reuniões nacionais 66 Encontro Nacional de Epileptologia 66 Normas para a organização de Encontro Nacionais de Epileptologia 68 Resumos de Comunicações 86 Reunião da Sociedade Portuguesa de Neurociências 87 Programa 96 Resumos de Comunicações 131 Fórum de Neurologia 2005 131 Programa 143 Resumos de Comunicações 179 Reunião do Grupo de Estudos de Esclerose Múltipla 179 Resumos de Comunicações 187 Órgãos Sociais e Comissões da SPN Volume 5 | N.º 1 | Maio de 2005 Sinapse 1 Princípios editoriais e normas de publicação Sinapse Publicação da Sociedade Portuguesa de Neurologia Princípios gerais acrescentada, se imprescindível, no fim do processo de avaliação · Publicação científica da Sociedade Portuguesa de Neurologia; e antes da edição do artigo. · Neurologia Clínica, como área principal; 10. As tabelas e figuras deverão ser enviadas em documento adicional · Especialidades afins e Neurociências, como interesses adicionais; Microsoft Word, uma por página, precedidas por uma página que ·Trabalhos transversais, integradores ou promotores da unidade da inclua as notas correspondentes. As figuras serão enviadas em GIF Neurologia, como vocação especial; ou JPEG. · Abertura e acessibilidade; 11. Os agradecimentos ou menções particulares constarão em página · Garantia de qualidade científica; própria. · Critérios de publicação de natureza científica e editorial; 12. Os compromissos particulares ou institucionais (patrocínios, · Aplicação sistemática das Normas de Vancouver; financiamentos, bolsas, prémios) serão expressos ·Organização formal em: Editorial, Artigos Originais, Casos Clínicos, obrigatoriamente em página adicional. Revisões, Cartas. · Periodicidade livre; Regras para elaboração do trabalho · Edição electrónica na página www.spneurologia.org; 1. Título · Edição em papel, e pontualmente, por outros meios (CD, outros); Será informativo, sem iniciais ou siglas, não excedendo vinte · Possibilidade de patrocínios institucionais ou comerciais; palavras. · Garantia de independência científica e editorial. 2. Autores e instituições A autoria exige, cumulativamente, contribuições substanciais para:
Load more

Recommended publications
  • Genetic Mutations and Mechanisms in Dilated Cardiomyopathy
    Genetic mutations and mechanisms in dilated cardiomyopathy Elizabeth M. McNally, … , Jessica R. Golbus, Megan J. Puckelwartz J Clin Invest. 2013;123(1):19-26. https://doi.org/10.1172/JCI62862. Review Series Genetic mutations account for a significant percentage of cardiomyopathies, which are a leading cause of congestive heart failure. In hypertrophic cardiomyopathy (HCM), cardiac output is limited by the thickened myocardium through impaired filling and outflow. Mutations in the genes encoding the thick filament components myosin heavy chain and myosin binding protein C (MYH7 and MYBPC3) together explain 75% of inherited HCMs, leading to the observation that HCM is a disease of the sarcomere. Many mutations are “private” or rare variants, often unique to families. In contrast, dilated cardiomyopathy (DCM) is far more genetically heterogeneous, with mutations in genes encoding cytoskeletal, nucleoskeletal, mitochondrial, and calcium-handling proteins. DCM is characterized by enlarged ventricular dimensions and impaired systolic and diastolic function. Private mutations account for most DCMs, with few hotspots or recurring mutations. More than 50 single genes are linked to inherited DCM, including many genes that also link to HCM. Relatively few clinical clues guide the diagnosis of inherited DCM, but emerging evidence supports the use of genetic testing to identify those patients at risk for faster disease progression, congestive heart failure, and arrhythmia. Find the latest version: https://jci.me/62862/pdf Review series Genetic mutations and mechanisms in dilated cardiomyopathy Elizabeth M. McNally, Jessica R. Golbus, and Megan J. Puckelwartz Department of Human Genetics, University of Chicago, Chicago, Illinois, USA. Genetic mutations account for a significant percentage of cardiomyopathies, which are a leading cause of conges- tive heart failure.
    [Show full text]
  • Limb-Girdle Muscular Dystrophy
    www.ChildLab.com 800-934-6575 LIMB-GIRDLE MUSCULAR DYSTROPHY What is Limb-Girdle Muscular Dystrophy? Limb-Girdle Muscular Dystrophy (LGMD) is a group of hereditary disorders that cause progressive muscle weakness and wasting of the shoulders and pelvis (hips). There are at least 13 different genes that cause LGMD, each associated with a different subtype. Depending on the subtype of LGMD, the age of onset is variable (childhood, adolescence, or early adulthood) and can affect other muscles of the body. Many persons with LGMD eventually need the assistance of a wheelchair, and currently there is no cure. How is LGMD inherited? LGMD can be inherited by autosomal dominant (AD) or autosomal recessive (AR) modes. The AR subtypes are much more common than the AD types. Of the AR subtypes, LGMD2A (calpain-3) is the most common (30% of cases). LGMD2B (dysferlin) accounts for 20% of cases and the sarcoglycans (LGMD2C-2F) as a group comprise 25%-30% of cases. The various subtypes represent the different protein deficiencies that can cause LGMD. What testing is available for LGMD? Diagnosis of the LGMD subtypes requires biochemical and genetic testing. This information is critical, given that management of the disease is tailored to each individual and each specific subtype. Establishing the specific LGMD subtype is also important for determining inheritance and recurrence risks for the family. The first step in diagnosis for muscular dystrophy is usually a muscle biopsy. Microscopic and protein analysis of the biopsy can often predict the type of muscular dystrophy by analyzing which protein(s) is absent. A muscle biopsy will allow for targeted analysis of the appropriate LGMD gene(s) and can rule out the diagnosis of the more common dystrophinopathies (Duchenne and Becker muscular dystrophies).
    [Show full text]
  • Anti-SGCG / Gamma Sarcoglycan Antibody (ARG41710)
    Product datasheet [email protected] ARG41710 Package: 100 μl anti-SGCG / gamma Sarcoglycan antibody Store at: -20°C Summary Product Description Rabbit Polyclonal antibody recognizes SGCG / gamma Sarcoglycan Tested Reactivity Hu Tested Application IHC-P, IP, WB Host Rabbit Clonality Polyclonal Isotype IgG Target Name SGCG / gamma Sarcoglycan Antigen Species Human Immunogen Synthetic peptide of Human SGCG / gamma Sarcoglycan Conjugation Un-conjugated Alternate Names 35DAG; DMDA1; TYPE; SCG3; DMDA; Gamma-sarcoglycan; DAGA4; 35 kDa dystrophin-associated glycoprotein; A4; SCARMD2; Gamma-SG; LGMD2C; MAM Application Instructions Application table Application Dilution IHC-P 1:50 - 1:200 IP 1:50 WB 1:500 - 1:2000 Application Note * The dilutions indicate recommended starting dilutions and the optimal dilutions or concentrations should be determined by the scientist. Calculated Mw 32 kDa Observed Size ~ 32 kDa Properties Form Liquid Purification Affinity purified. Buffer PBS (pH 7.4), 150 mM NaCl, 0.02% Sodium azide and 50% Glycerol. Preservative 0.02% Sodium azide Stabilizer 50% Glycerol Storage instruction For continuous use, store undiluted antibody at 2-8°C for up to a week. For long-term storage, aliquot and store at -20°C. Storage in frost free freezers is not recommended. Avoid repeated freeze/thaw cycles. Suggest spin the vial prior to opening. The antibody solution should be gently mixed before use. www.arigobio.com 1/2 Note For laboratory research only, not for drug, diagnostic or other use. Bioinformation Gene Symbol SGCG Gene Full Name sarcoglycan, gamma (35kDa dystrophin-associated glycoprotein) Background This gene encodes gamma-sarcoglycan, one of several sarcolemmal transmembrane glycoproteins that interact with dystrophin.
    [Show full text]
  • Full Disclosure Forms
    Expanding genotype/phenotype of neuromuscular diseases by comprehensive target capture/NGS Xia Tian, PhD* ABSTRACT * Wen-Chen Liang, MD Objective: To establish and evaluate the effectiveness of a comprehensive next-generation * Yanming Feng, PhD sequencing (NGS) approach to simultaneously analyze all genes known to be responsible for Jing Wang, MD the most clinically and genetically heterogeneous neuromuscular diseases (NMDs) involving spi- Victor Wei Zhang, PhD nal motoneurons, neuromuscular junctions, nerves, and muscles. Chih-Hung Chou, MS Methods: All coding exons and at least 20 bp of flanking intronic sequences of 236 genes causing Hsien-Da Huang, PhD NMDs were enriched by using SeqCap EZ solution-based capture and enrichment method fol- Ching Wan Lam, PhD lowed by massively parallel sequencing on Illumina HiSeq2000. Ya-Yun Hsu, PhD ; 3 Thy-Sheng Lin, MD Results: The target gene capture/deep sequencing provides an average coverage of 1,000 per Wan-Tzu Chen, MS nucleotide. Thirty-five unrelated NMD families (38 patients) with clinical and/or muscle pathologic Lee-Jun Wong, PhD diagnoses but without identified causative genetic defects were analyzed. Deleterious mutations Yuh-Jyh Jong, MD were found in 29 families (83%). Definitive causative mutations were identified in 21 families (60%) and likely diagnoses were established in 8 families (23%). Six families were left without diagnosis due to uncertainty in phenotype/genotype correlation and/or unidentified causative Correspondence to genes. Using this comprehensive panel, we not only identified mutations in expected genes but Dr. Wong: also expanded phenotype/genotype among different subcategories of NMDs. [email protected] or Dr. Jong: Conclusions: Target gene capture/deep sequencing approach can greatly improve the genetic [email protected] diagnosis of NMDs.
    [Show full text]
  • Fukuyama-Type Congenital Muscular Dystrophy and Abnormal
    Fukuyama-type Congenital Muscular Dystrophy and Abnormal Glycosylation of α-Dystroglycan Tatsushi Toda, Kazuhiro Kobayashi, Satoshi Takeda(1), Junko Sasaki, Hiroki Kurahashi, Hiroki Kano, Masaji Tachikawa, Fan Wang, Yoshitaka Nagai, Kiyomi Taniguchi, Mariko Taniguchi, Yoshihide Sunada(2), Toshio Terashima(3), Tamao Endo(4) and Kiichiro Matsumura(5) Division of Functional Genomics, Department of Post-Genomics and Diseases, Osaka University Graduate School of Medicine, Suita, (1) Otsuka GEN Research Institute, Otsuka Pharmaceutical Co. Ltd., Tokushima, (2) Department of Neurology, Kawasaki Medical School, Kurashiki, (3) Department of Anatomy and Neurobiology, Kobe University Graduate School of Medicine, Kobe, (4) Glycobiology Research Group, Tokyo Metropolitan Institute of Gerontology, Tokyo and (5) Department of Neurology, Teikyo University School of Medicine, Tokyo, Japan Abstract Fukuyama-type congenital muscular dystrophy (FCMD), Walker-Warburg syndrome (WWS), and muscle-eye-brain (MEB) disease are clinically similar autosomal recessive disorders characterized by congenital muscular dystrophy, lissencephaly, and eye anomalies. We identified the gene for FCMD and MEB, which encodes the fukutin protein and the protein O-linked mannose β1, 2-N-acetylglucosaminyltransferase (POMGnT1), respectively. α-dystroglycan is a key component of the dystrophin-glycoprotein-complex, providing a tight linkage between the cell and basement membranes by binding laminin via its carbohydrate residues. Recent studies have revealed that posttranslational
    [Show full text]
  • Diagnosis and Cell-Based Therapy for Duchenne Muscular Dystrophy in Humans, Mice, and Zebrafish
    J Hum Genet (2006) 51:397–406 DOI 10.1007/s10038-006-0374-9 MINIREVIEW Louis M. Kunkel Æ Estanislao Bachrach Richard R. Bennett Æ Jeffrey Guyon Æ Leta Steffen Diagnosis and cell-based therapy for Duchenne muscular dystrophy in humans, mice, and zebrafish Received: 3 January 2006 / Accepted: 4 January 2006 / Published online: 1 April 2006 Ó The Japan Society of Human Genetics and Springer-Verlag 2006 Abstract The muscular dystrophies are a heterogeneous mutants carries a stop codon mutation in dystrophin, group of genetically caused muscle degenerative disor- and we have recently identified another carrying a ders. The Kunkel laboratory has had a longstanding mutation in titin. We are currently positionally cloning research program into the pathogenesis and treatment of the disease-causative mutation in the remaining 12 mu- these diseases. Starting with our identification of dys- tant strains. We hope that one of these new mutant trophin as the defective protein in Duchenne muscular strains of fish will have a mutation in a gene not previ- dystrophy (DMD), we have continued our work on ously implicated in human muscular dystrophy. This normal dystrophin function and how it is altered in gene would become a candidate gene to be analyzed in muscular dystrophy. Our work has led to the identifi- patients which do not carry a mutation in any of the cation of the defective genes in three forms of limb girdle known dystrophy-associated genes. By studying both muscular dystrophy (LGMD) and a better understand- disease pathology and investigating potential therapies, ing of how muscle degenerates in many of the different we hope to make a positive difference in the lives of dystrophies.
    [Show full text]
  • Analysis of the Dystrophin Interactome
    Analysis of the dystrophin interactome Dissertation In fulfillment of the requirements for the degree “Doctor rerum naturalium (Dr. rer. nat.)” integrated in the International Graduate School for Myology MyoGrad in the Department for Biology, Chemistry and Pharmacy at the Freie Universität Berlin in Cotutelle Agreement with the Ecole Doctorale 515 “Complexité du Vivant” at the Université Pierre et Marie Curie Paris Submitted by Matthew Thorley born in Scunthorpe, United Kingdom Berlin, 2016 Supervisor: Simone Spuler Second examiner: Sigmar Stricker Date of defense: 7th December 2016 Dedicated to My mother, Joy Thorley My father, David Thorley My sister, Alexandra Thorley My fiancée, Vera Sakhno-Cortesi Acknowledgements First and foremost, I would like to thank my supervisors William Duddy and Stephanie Duguez who gave me this research opportunity. Through their combined knowledge of computational and practical expertise within the field and constant availability for any and all assistance I required, have made the research possible. Their overarching support, approachability and upbeat nature throughout, while granting me freedom have made this year project very enjoyable. The additional guidance and supported offered by Matthias Selbach and his team whenever required along with a constant welcoming invitation within their lab has been greatly appreciated. I thank MyoGrad for the collaboration established between UPMC and Freie University, creating the collaboration within this research project possible, and offering research experience in both the Institute of Myology in Paris and the Max Delbruck Centre in Berlin. Vital to this process have been Gisele Bonne, Heike Pascal, Lidia Dolle and Susanne Wissler who have aided in the often complex processes that I am still not sure I fully understand.
    [Show full text]
  • Genetic Modifiers of Hereditary Neuromuscular Disorders
    cells Article Genetic Modifiers of Hereditary Neuromuscular Disorders and Cardiomyopathy Sholeh Bazrafshan 1, Hani Kushlaf 2 , Mashhood Kakroo 1, John Quinlan 2, Richard C. Becker 1 and Sakthivel Sadayappan 1,* 1 Heart, Lung and Vascular Institute, Division of Cardiovascular Health and Disease, Department of Internal Medicine, University of Cincinnati College of Medicine, Cincinnati, OH 45267, USA; [email protected] (S.B.); [email protected] (M.K.); [email protected] (R.C.B.) 2 Department of Neurology and Rehabilitation Medicine, Neuromuscular Center, University of Cincinnati Gardner Neuroscience Institute, University of Cincinnati College of Medicine, Cincinnati, OH 45267, USA; [email protected] (H.K.); [email protected] (J.Q.) * Correspondence: [email protected]; Tel.: +1-513-558-7498 Abstract: Novel genetic variants exist in patients with hereditary neuromuscular disorders (NMD), including muscular dystrophy. These patients also develop cardiac manifestations. However, the association between these gene variants and cardiac abnormalities is understudied. To determine genetic modifiers and features of cardiac disease in NMD patients, we have reviewed electronic medical records of 651 patients referred to the Muscular Dystrophy Association Care Center at the University of Cincinnati and characterized the clinical phenotype of 14 patients correlating with their next-generation sequencing data. The data were retrieved from the electronic medical records of the 14 patients included in the current study and comprised neurologic and cardiac phenotype and genetic reports which included comparative genomic hybridization array and NGS. Novel associations were uncovered in the following eight patients diagnosed with Limb-girdle Muscular Dystrophy, Bethlem Myopathy, Necrotizing Myopathy, Charcot-Marie-Tooth Disease, Peripheral Citation: Bazrafshan, S.; Kushlaf, H.; Kakroo, M.; Quinlan, J.; Becker, R.C.; Polyneuropathy, and Valosin-containing Protein-related Myopathy.
    [Show full text]
  • ACTA PEDIÁTRICA PORTUGUESA Vol 43 Nº 5 Setembro / Outubro 2012 ­‑ Suplemento I (Orgão Oficial Da Sociedade Portuguesa De Pediatria) ­‑ [email protected]
    S I ACTA PEDIÁTRICA PORTUGUESA VOl 43 Nº 5 SETEmbRO / OUTUbRO 2012 ‑ SUPlEmento I (Orgão Oficial da Sociedade Portuguesa de Pediatria) www.spp.pt ‑ [email protected] FundadOr Carlos Salazar de Sousa CONSELHO EDITORIAL Conselho Científico Aguinaldo Cabral (Sociedade Portuguesa de D. Metabólicas) Diretor Almerinda Pereira (Secção de Neonatologia) João m. Videira Amaral ‑ Lisboa Ana Cadete (Secção de Reabilitação Pediátrica da SPMFR) Deolinda barata (Pediatria Social) Editores Associados Fernando Pereira (Secção de Gastrenterologia e Nutrição) Guiomar Oliveira ‑ Coimbra Ana medeira (Sociedade Portuguesa de Genética Humana) Jorge Amil Dias ‑ Porto Ana Xavier (Grupo Port. de Oftalmologia Ped. e Estrabismo) luís Pereira‑da‑Silva ‑ Lisboa Alberto Caldas Afonso (Secção de Nefrologia) Coordenador de EdiçãO Filomena Pereira (Secção de Hematologia e Oncologia) António Gomes ‑ Almada Guiomar Oliveira (Sociedade de Neurodesenvolvimento) João Gomes‑Pedro (Secção de Educação Médica) Secretariado José Frias bulhosa (Ordem dos Médicos Dentistas) maria Júlia brito ‑ SPP Graça Rocha (Sociedade de Infeciologia) leonor Sassetti (Secção de Pediatria Ambulatória) libério Ribeiro (Secção de Imuno‑Alergologia) lurdes lisboa Editores Correspondentes (Secção de Cuidados Intensivos) manuel Salgado (Secção de Reumatologia) (Países de Língua OficiaL POrtuguesa) maria Ana Sampaio Nunes (Sociedade de Cardiologia Pediátrica) luís bernardino ‑ Angola miguel Coutinho (Subcomissão de ORL Pediátrica da SPORL) Paula Vaz ‑ Moçambique mário marcelo da Fonseca (Secção de Endocrinologia)
    [Show full text]
  • Muscle Diseases: the Muscular Dystrophies
    ANRV295-PM02-04 ARI 13 December 2006 2:57 Muscle Diseases: The Muscular Dystrophies Elizabeth M. McNally and Peter Pytel Department of Medicine, Section of Cardiology, University of Chicago, Chicago, Illinois 60637; email: [email protected] Department of Pathology, University of Chicago, Chicago, Illinois 60637; email: [email protected] Annu. Rev. Pathol. Mech. Dis. 2007. Key Words 2:87–109 myotonia, sarcopenia, muscle regeneration, dystrophin, lamin A/C, The Annual Review of Pathology: Mechanisms of Disease is online at nucleotide repeat expansion pathmechdis.annualreviews.org Abstract by Drexel University on 01/13/13. For personal use only. This article’s doi: 10.1146/annurev.pathol.2.010506.091936 Dystrophic muscle disease can occur at any age. Early- or childhood- onset muscular dystrophies may be associated with profound loss Copyright c 2007 by Annual Reviews. All rights reserved of muscle function, affecting ambulation, posture, and cardiac and respiratory function. Late-onset muscular dystrophies or myopathies 1553-4006/07/0228-0087$20.00 Annu. Rev. Pathol. Mech. Dis. 2007.2:87-109. Downloaded from www.annualreviews.org may be mild and associated with slight weakness and an inability to increase muscle mass. The phenotype of muscular dystrophy is an endpoint that arises from a diverse set of genetic pathways. Genes associated with muscular dystrophies encode proteins of the plasma membrane and extracellular matrix, and the sarcomere and Z band, as well as nuclear membrane components. Because muscle has such distinctive structural and regenerative properties, many of the genes implicated in these disorders target pathways unique to muscle or more highly expressed in muscle.
    [Show full text]
  • Table E-2. Distinguishing Features of Muscular Dystrophies Designation
    Table e-2. Distinguishing features of muscular dystrophies Designation Protein Chromosome Inheritance Common Distinguishing Distinguishing EMG Complications patterns of clinical features and muscle biopsy weakness features X-linked muscular dystrophies EDMD-X1 Emerin Xq28 XR HP Contractures Cardiac invariably present conduction early in the disease abnormalities course EDMD-X2 FHL1 Xq27.2 XR LG, HP or Foot drop; extremity Myofibrillar myopathy Severe SP, DM contractures and or reducing bodies respiratory neck contractures failure in many common patients Becker Dystrophin Xp21 XR LG Calf hypertrophy Mosaic appearance of Dilated muscular dystrophin on cardiomyopathy dystrophy immunohistochemistry in 4% to 70% in affected woman depending on disease duration Limb-girdle muscular dystrophies (LGMDs) LGMD1A Myotilin 5q22.3-31.3 AD LG, DM Onset > 40 years, Myofibrillar myopathy, Cardiomyopathy, foot drop, myotonic or respiratory asymmetric muscle pseudomyotonic muscle weakness weakness and discharges atrophy LGMD1B Lamin A/C 1q11-21 AD LG, HP, DM Early Cardiomyopathy humeroperoneal and conduction weakness, limb system disease contractures LGMD1C Caveolin-3 3p25 AD LG Rippling muscles, percussion-induced rapid contractions, prominent muscle cramps and calf hypertrophy LGMD1D DNAJB6 6q23 AD LG, DM Onset > 40 years, Myofibrillar myopathy, foot drop rimmed vacuoles, myotonic or pseudomyotonic discharges LGMD1E Desmin 2q35 AD LG, HP, DM Onset < 40 years, Myofibrillar myopathy, Cardiomyopathy, foot drop myotonic or respiratory pseudomyotonic muscle
    [Show full text]
  • The Congenital and Limb-Girdle Muscular Dystrophies Sharpening the Focus, Blurring the Boundaries
    NEUROLOGICAL REVIEW SECTION EDITOR: DAVID E. PLEASURE, MD The Congenital and Limb-Girdle Muscular Dystrophies Sharpening the Focus, Blurring the Boundaries Janbernd Kirschner, MD; Carsten G. Bo¨nnemann, MD uring the past decade, outstanding progress in the areas of congenital and limb- girdle muscular dystrophies has led to staggering clinical and genetic complexity. With the identification of an increasing number of genetic defects, individual enti- ties have come into sharper focus and new pathogenic mechanisms for muscular dys- Dtrophies, like defects of posttranslational O-linked glycosylation, have been discovered. At the same time, this progress blurs the traditional boundaries between the categories of congenital and limb- girdle muscular dystrophies, as well as between limb-girdle muscular dystrophies and other clini- cal entities, as mutations in genes such as fukutin-related protein, dysferlin, caveolin-3 and lamin A/C can cause a striking variety of phenotypes. We reviewed the different groups of proteins cur- rently recognized as being involved in congenital and limb-girdle muscular dystrophies, associ- ated them with the clinical phenotypes, and determined some clinical and molecular clues that are helpful in the diagnostic approach to these patients. Arch Neurol. 2004;61:189-199 Muscular dystrophies were first recog- phy. The age at onset may range from early nized as a disease entity with the detailed childhood to late adulthood.5 description of the clinical presentation of During the past decade, exciting Duchenne muscular dystrophy in 1852 and progress has been made in the field of CMD thereafter.1,2 About 50 years later, Batten3 and LGMD, emphasizing differences as published the first case reports of a con- well as commonalities between them.
    [Show full text]